Northwestern

GlobalData report highlights staggering economic costs for Illinois of $17.6 billion due to obesity

Retrieved on: 
Wednesday, March 6, 2024
Diabetes, Publishing, Human Resources, Healthcare Reform, Labor, Communications, Other Consumer, General Health, Professional Services, Women, Public Policy, Government, Men, Fitness & Nutrition, Consumer, Data Analytics, Health, Woman, Research, Eli Lilly and Company, GlobalData, Overweight, Education, Lurie, Quality of life, Weight loss, Culture, Northwestern, Conditional sentence, Federation, Prevalence, Welfare, Medicare, DSM-IV codes, Head, Death, Associate, Disease, Workforce, Comment, Parity, Insurance, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on Illinois' Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Illinois, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on Illinois' Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Illinois, as well as the impact on state tax revenue collections and costs.
  • In Illinois, approximately one-third of adults are classified as having obesity (33.4%), and another third have overweight (33.9%) in 2022.
  • Employers in Illinois paid an extra $2.1 billion in higher medical expenditures for health complications attributed to obesity and overweight.
  • The federal government also spent an estimated $3.7 billion more on Medicare and Medicaid for Illinois residents.

CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)

Retrieved on: 
Thursday, February 22, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Phloroglucinol, IBS-D, Inflammation, Physician, Pain, Northwestern, Spasm, Patient, Clinical trial, IBS, Pharmaceutical industry

CinPhloro Pharma, a CinRx portfolio company advancing CIN-103 as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D), today announced the first clinical trial participant has been dosed in its Phase 2 enviva study.

Key Points: 
  • CinPhloro Pharma, a CinRx portfolio company advancing CIN-103 as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D), today announced the first clinical trial participant has been dosed in its Phase 2 enviva study.
  • CIN-103, a novel formulation of phloroglucinol intended for long-term use, is a non-opioid based small molecule designed to address multiple IBS-D action points including motility, secretion, pain, spasms and inflammation.
  • “I am encouraged by early studies of CIN-103 demonstrating a superior PK profile and absence of anticholinergic side effects compared to other antispasmodics like phloroglucinol.
  • Ongoing research involving CIN-103 holds promise for improving global symptoms in patients with IBS-D.”

The Joint Commission Enterprise announces two officer appointments to executive leadership team

Retrieved on: 
Tuesday, December 19, 2023
Marketing, Merative, Argonne National Laboratory, Journalism, Patient safety, MD, Doctor of Philosophy, MACP, Michigan State University, University, COVID-19, Joint, Safety, Northwestern, Organization, Nielsen, Sara Lee Corporation, MSHA, Management

OAKBROOK TERRACE, Illinois, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The Joint Commission Enterprise today announced two appointments to its executive leadership team: Leslie Krohn, MS, has been named executive vice president and chief brand and communications officer, and Jason Miles has been named vice president and U.S. commercial officer.

Key Points: 
  • OAKBROOK TERRACE, Illinois, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The Joint Commission Enterprise today announced two appointments to its executive leadership team: Leslie Krohn, MS, has been named executive vice president and chief brand and communications officer, and Jason Miles has been named vice president and U.S. commercial officer.
  • “We are excited to welcome these two innovative leaders to help The Joint Commission Enterprise advance its mission to elevate patient safety, quality improvement and equitable care,” says Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, president and chief executive officer, The Joint Commission Enterprise.
  • In her new appointment, Krohn will help The Joint Commission Enterprise advance its patient safety and quality improvement initiatives.
  • Reporting to Jean Courtney, executive vice president and chief operating officer, The Joint Commission Enterprise, Miles’ appointment became effective Dec. 4, 2023.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Monday, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

Clever Carnivore Raises $7M to Expand Operations and Scale Up Production of Cultivated Meat

Retrieved on: 
Monday, December 4, 2023
Start-Up, Biotechnology, Technology, Professional Services, Health, Food, Beverage, Other Science, Research, Retail, Science, Food Tech, Human, Northwestern, Animal, Bioreactor, Meat, Carnivore, Immortalised cell line, Taste, Aquaculture, Fine chemical

And early investors in Clever Carnivore will be among the first to see how the sausage gets made.

Key Points: 
  • And early investors in Clever Carnivore will be among the first to see how the sausage gets made.
  • Clever Carnivore, a Chicago biotech startup producing low-cost, top-quality cultivated meat, today announced the successful closing of its $7 million seed round funding.
  • “We are delighted with the enthusiastic support from our investors in this seed round,” said Virginia Rangos, Ph.D., CEO and co-founder of Clever Carnivore.
  • Clever Carnivore is currently producing cultivated pork sausage, with plans to unveil its prototype product, the Clever Bratwurst, in early 2024.

Rice Biotech Launch Pad announces rechargeable oxygenator in development to improve cell-based therapies

Retrieved on: 
Thursday, November 9, 2023
Science, Survival, Faculty, Rice University, Water, CMU, Therapy, Obesity, Metal, Oxygen, Insulin autoimmune syndrome, Diabetes, DARPA, Electricity, Research, Cell, Chlorine, Engineering, Hydrogen, Carnegie Mellon University, Tissue, Injury, Nature Communications, Cancer, College of Engineering (KNUST), Chemistry, Biomedical engineering, Wound healing, Northwestern University in Qatar, Hydrogen peroxide, Pharmaceutical industry, Medical device, Northwestern

The implantable "living pharmacy" is a device in development at the Rice Biotech Launch Pad with the goal to autonomously administer and regulate therapeutics within an individual.

Key Points: 
  • The implantable "living pharmacy" is a device in development at the Rice Biotech Launch Pad with the goal to autonomously administer and regulate therapeutics within an individual.
  • "This breakthrough technology has the potential to reshape the landscape of disease treatment and the future of research and development in the field of cell-based therapies.
  • We are working toward advancing this technology into the clinic to bring it one step closer to those in need."
  • Cell-based therapies hold great potential to treat many different types of diseases including endocrine disorders, autoimmune syndromes, cancers and neurological degeneration.

Winston & Strawn Files Lawsuit on Behalf of Former Northwestern University Football Coach Pat Fitzgerald Against Northwestern and University President Michael Schill

Retrieved on: 
Thursday, October 5, 2023
Legal, Professional Services, Circuit Court of Cook County, International law, Family, Schill, LLP, Winston & Strawn, Employment, Defamation, Medicine, Hazing, Athlete, Sports equipment, Northwestern

Winston & Strawn LLP announced today that a Winston team led by litigation partners Dan K. Webb and Matthew R. Carter filed a lawsuit in Cook County Circuit Court on behalf of Pat Fitzgerald, Northwestern University’s former head football coach.

Key Points: 
  • Winston & Strawn LLP announced today that a Winston team led by litigation partners Dan K. Webb and Matthew R. Carter filed a lawsuit in Cook County Circuit Court on behalf of Pat Fitzgerald, Northwestern University’s former head football coach.
  • Northwestern and university president Michael Schill are the named defendants.
  • The suit seeks in excess of $130 million in compensatory damages and as-yet unspecified damages for emotional distress and punitive damages.
  • None of the players interviewed was able to point to a specific instance of misconduct by a Northwestern football player or coach.

Foley Foundation to launch a new Journalist Safety Task Force at a National Press Club Headliners Newsmaker event on Monday, Oct. 16

Retrieved on: 
Friday, October 13, 2023
Multimedia, Press club, Medill School of Journalism, Risk, Human voice, Club, D.C, National Press Club (United States), Emerita, Agence France-Presse, ISIS, Chairperson, Journalism, Roosevelt, Marquette University, The New York Times, Marquette, Publishing, Northwestern, Northwestern University, NW

As war rages in the Gaza region and correspondents are working at risk in active war zones, this timely panel on reporting in conflict zones will address journalist safety training.

Key Points: 
  • As war rages in the Gaza region and correspondents are working at risk in active war zones, this timely panel on reporting in conflict zones will address journalist safety training.
  • He had been covering the Syrian civil war for Global Post and Agence France Presse at the time of his capture.
  • The Foley Foundation advocates for the safe return of all Americans held hostage and provides journalist safety education.
  • The National Press Club is located on the 13th Floor of the National Press Building at 529 14th St., NW, Washington, D.C.
    PRESS CONTACT: Cecily Scott Martin for the National Press Club; [email protected] ; (202) 662-7525
    View original content to download multimedia: https://www.prnewswire.com/news-releases/foley-foundation-to-launch-a-ne...

Poets&Quants™ Names Ann Harrison Dean of the Year in Annual Honors

Retrieved on: 
Tuesday, October 10, 2023
Teaching, MBA, University of Washington Information School, Rotman School of Management, Entrepreneurship, Research, Faculty, Poet, Economics, Haas School of Business, Yale school, Berkeley, Culture, Indiana University East, Gies College of Business, Kelley School of Business, Foster School of Business, University, Dartmouth College, Stanford Graduate School of Business, Kellogg School of Management, World Bank, Indiana University, University of Toronto Faculty of Law, University of Virginia School of Law, Triple accreditation, Champaign–Urbana metropolitan area, IE Business School, University of California, Berkeley, Tuck School of Business, Yale School of Management, Woman, Harvard Business School, University of Virginia Darden School of Business, Nightclub, Management, Business, Northwestern, Dean, Princeton University

BERKELEY, Calif., Oct. 10, 2023 /PRNewswire/ -- Poets&Quants the definitive online publication for business education news, has named Ann Harrison from the Haas School of Business at the University of California, Berkeley. Dean of the Year.

Key Points: 
  • Dean of the Haas School of Business, University of California, Berkeley is the 13th dean to receive this honor
    BERKELEY, Calif., Oct. 10, 2023 /PRNewswire/ -- Poets&Quants the definitive online publication for business education news, has named Ann Harrison from the Haas School of Business at the University of California, Berkeley.
  • Her drive and vision have made sure that a rising tide will never overtake the island on which Haas firmly stands."
  • Harrison earned her Ph.D. from Princeton in 1991 and remained at the World Bank until 1994.
  • To learn more about the Poets&Quants Dean of the Year, please visit https://poetsandquants.com/2023/10/04/dean-of-the-year-ann-harrison-of-u...

SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Clinical Trials, Medical Devices, RA, Defecation, TNF, Gastrointestinal tract, Vagus nerve, Serum, Disease, Quality of life, Vagus nerve stimulation, Inflammation, Doctor of Philosophy, Rheumatoid arthritis, Inflammatory bowel disease, Crohn's disease, Journal, Medical director, MD, Patient, Gastroenterology, CDAI, Safety, Northwestern, Pharmaceutical industry, Colitis, Medicine

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .
  • The pilot study demonstrated that neuroimmune modulation via vagus nerve stimulation resulted in a clinically meaningful reduction in disease activity and improved quality of life.
  • “Crohn’s disease is a debilitating inflammatory condition affecting the gastrointestinal tract.
  • “We are committed to advancing the potential of neuroimmune modulation for patients suffering from various chronic autoimmune conditions,” said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical.